PBF 677

Drug Profile

PBF 677

Alternative Names: PBF-677

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palobiofarma
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Irritable bowel syndrome

Most Recent Events

  • 27 Sep 2016 Phase-I clinical trials in Irritable bowel syndrome in Spain (PO) prior to September 2016
  • 01 Dec 2015 Phase-I clinical trials in Glaucoma (In volunteers) in Spain (PO) (NCT02639975)
  • 01 Dec 2014 Preclinical trials in Irritable bowel syndrome and Glaucoma in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top